This is a paid press release. Contact the press release distributor directly with any enquiries.
insitro Designed <a href="https://myappsplus.com/machine-learning-algorithm-predicts-shib-price-on-october-31-2026/” title=”Machine learning algorithm predicts SHIB price on October 31, 2026″>Machine Learning Models for Small Molecule in vivo Pharmacokinetic Behavior Prediction Now Available in Lilly TuneLab
SOUTH SAN FRANCISCO, Calif., October 06, 2026–(BUSINESS WIRE)–insitro, the AI company unlocking causal human biology to systematically generate high-impact therapeutics, today announced that the advanced machine learning models that insitro built with Eli Lilly and Company (Lilly) to predict in vitroand, critically, in vivoproperties of small molecules can now be used by certain biotech companies in Lilly TuneLab™. Trained on multi-species preclinical data that Lilly generated over decades of research from hundreds of thousands of unique molecules, the models offer a powerful alternative to today’s industry standard method of extrapolation from in vitro assays, providing an enterprise-grade capability traditionally available only to organizations with the scale to generate such data volumes themselves. The models will be updated as the dataset continues to expand.
Announced in September 2025, the collaboration paired insitro’s computational and AI/ML expertise with Lilly’s proprietary preclinical dataset of in vitro and in vivo measurements from a wide array of compounds with established ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) properties, derived from decades of Lilly drug discovery, and representing a world-class dataset in quality, consistency and scale. This collaboration demonstrates the power of insitro’s platform by combining insitro’s AI and ML expertise with Lilly’s data to unlock and advance small molecule development.
“Nine in 10 programs that enter the clinic fail, most often when we first test for efficacy. That happens when the mechanism did not drive the disease, but also when the molecule never reaches the tissue at the right concentration for the right duration,” said Daphne Koller, Ph.D., founder and CEO of insitro. “The question of a molecule’s in vivobehavior has been an empirical question, answered experimentally, slowly, one compound at a time. These models make it a computational question first.”
The downstream implications extend to patients. Most small molecule candidates fail, often for pharmacokinetic or safety reasons that surface late, after significant time and capital have been committed. Better prediction at the design stage may mean that fewer candidates advance on flawed structures, promising molecules reach the clinic on shorter timelines, and program development becomes more tractable. Improved in silicoprediction also supports reduced reliance on animal studies, which aligns with the goals in FDA’s April 2025 Roadmap to Reducing Animal Testing in Preclinical Safety Studies and its March 2026 draft guidance on new approach methodologies.
